JP Morgan Maintains Neutral on Nektar Therapeutics, Lowers Price Target to $28

JP Morgan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and lowers the price target from $33 to $28.

Benzinga · 11/13/2019 13:53

JP Morgan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and lowers the price target from $33 to $28.